The Company

Sentinel Oncology was founded in 2005 with the vision of developing an innovative strategy for cancer treatment, ‘Targeted Synergy’ in which a single drug can be engineered to deliver two distinct activities to the unique microenvironment of a solid tumour. In 2007, Sentinel Oncology received the much sought after Wellcome Trust Seeding Drug Discovery award for the development of Targeted Synergy and has built a pipeline of drug discovery projects.

Sentinel has assembled a group of highly motivated investors and advisors that collectively bring complementary skills and experience in finance, biotech and drug discovery to lead the development of our drug pipeline.

Sentinel Oncology is based in Cambridge, UK and has established a completely virtual drug discovery model which we estimate is significantly more capital efficient than a more traditional biotech model incorporating in house discovery and development capability.